As healthcare spending is estimated to double by 2050, making up to 30 percent of GDP in some economies, the concept of nutrigenomics and personalised nutrition is increasingly becoming a priority. The question still remains how much of the innovation and new technology currently being introduced to the market is actually available and affordable to the mass market; with the very definition of personalised nutrition focusing on the importance of meeting individual nutrition requirements, is it commercially possible for the industry to deliver? Dr Iris Hardewig, director of consulting and strategic innovation at analyze & realize GmbH, will be speaking about personalised nutrition on the Innovation Theatre at Vitafoods Asia 2017 in September and joins us to introduce the topic.
Vitafoods Insights is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.